Literature DB >> 1515758

Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis.

M R Morsi1, E H Madina, A A Anglo, A T Soliman.   

Abstract

We have evaluated the effect of oral captopril versus a combination of oral reserpine and frusemide in the treatment of 20 children with post-streptococcal glomerulonephritis (APGN) with hypertension. Captopril produced a significantly greater reduction in systolic and diastolic blood pressure in both the standing and supine positions than reserpine + frusemide at 0.75, 1, 1.25, 8, 24, 48 and 72 h after initiating treatment. Neither postural hypotension nor reflex tachycardia accompanied the therapeutic effect of captopril. Blood urea, serum creatinine and creatinine clearance did not change significantly after therapy in either study group. Three days after initiating treatment, the 24 h urinary catecholamine output increased significantly in children who received captopril but did not change in children treated with frusemide and reserpine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515758     DOI: 10.1111/j.1651-2227.1992.tb12191.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  3 in total

Review 1.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Streptococcal zymogen type B induces angiotensin II in mesangial cells and leukocytes.

Authors:  Ninoska Viera; Adriana Pedreanez; Jaimar Rincon; Jesus Mosquera
Journal:  Pediatr Nephrol       Date:  2009-01-29       Impact factor: 3.714

3.  Atypical presentation of acute post-infectious glomerulonephritis in patients with sickle cell disease: report of two cases.

Authors:  Precil Diego Miranda de Menezes Neves; Bernardo Vergara Reichert; Ramaiane Aparecida Bridi; Luis Yu; Cristiane Bitencourt Dias; Rafaela Brito Bezerra Pinheiro; Leonardo de Abreu Testagrossa; Lívia Barreira Cavalcante; Denise Maria Avancini Costa Malheiros; Lectícia Barbosa Jorge; Viktoria Woronik
Journal:  BMC Nephrol       Date:  2020-02-24       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.